Julia Hatto
Publications by Year
Research Areas
Asthma and respiratory diseases, Receptor Mechanisms and Signaling, Crystallization and Solubility Studies, Phosphodiesterase function and regulation, X-ray Diffraction in Crystallography
Most-Cited Works
- → The Identification of Indacaterol as an Ultralong-Acting Inhaled β2-Adrenoceptor Agonist(2010)100 cited
- → Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway(2012)47 cited
- → Discovery of Icenticaftor (QBW251), a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator with Clinical Efficacy in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease(2021)35 cited
- → Solubility-Driven Optimization of Phosphodiesterase-4 Inhibitors Leading to a Clinical Candidate(2012)33 cited
- → Discovery of Fevipiprant (NVP-QAW039), a Potent and Selective DP2 Receptor Antagonist for Treatment of Asthma(2017)33 cited
- → A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential(2005)31 cited
- → Synthesis of derivatives of muramic acid and C-1 homologated α-D-glucose as potential inhibitors of bacterial transglycosylase(1995)28 cited
- → Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)(2015)18 cited
- → Potent and selective xanthine-based inhibitors of phosphodiesterase 5(2006)12 cited
- → Early Process Development of a Squaramide-Based CXCR2 Receptor Antagonist(2015)9 cited